Acrocal D

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acrocal D

Property Description
Active ingredient Calcium Carbonate, Dihydrotachysterol
Form Oral tablet or capsule
Pharmacological class Mineral Supplement and Calcitrophic Agent Combination
Common use Supporting mineral and bone health
Origin Mineral (Calcium Carbonate), Synthetic Analog (Dihydrotachysterol)

The Pharmacological Identity of Acrocal D

Acrocal D is defined as an oral combination product containing the active ingredients Calcium Carbonate and Dihydrotachysterol. Pharmacologically, it is classified as a Mineral Supplement and Calcitrophic Agent Combination, integrating both a source of essential elemental calcium and a potent regulator of mineral metabolism. It is typically prepared as a solid oral dosage form, such as an oral tablet or oral capsule.

This fixed formulation is clinically recognized for its role in specialized mineral management, providing comprehensive support for the stability of calcium homeostasis. The maintenance of this physiological state is crucial for functions like skeletal system integrity, nerve transmission, and muscle contraction.

Composition: Calcium Carbonate and the Specialized Dihydrotachysterol

The composition includes Calcium Carbonate, an inorganic salt serving as the principal source of calcium, and Dihydrotachysterol (DHT), which is a synthetic analog of Vitamin D2. The Calcium Carbonate component provides the necessary mineral substrate, while Dihydrotachysterol functions as a powerful calcitrophic agent that controls how the body utilizes the mineral.

Dihydrotachysterol differs structurally from standard Vitamin D2 (Ergocalciferol) and Vitamin D3 (Cholecalciferol). This synthetic analog is characterized by an activation process that bypasses the primary kidney-based hydroxylation step required for natural Vitamin D forms. This feature means the body can more readily activate this ingredient, making it a key factor in enhanced mineral regulation for certain patient needs.

General Purpose: The Dual Role in Mineral Support

The general purpose of Acrocal D is the robust and enhanced maintenance of the body's mineral balance, specifically targeting deficiencies in calcium and Vitamin D pathway function. A typical, neutral use scenario involves patients requiring reliable and consistent support for bone health due to ongoing mineral instability. The combination works by simultaneously replenishing elemental calcium reserves and activating the physiological mechanisms that increase intestinal absorption of calcium, assisting in conditions where controlled, enhanced calcium regulation is necessary.

Regulatory References

  1. NIH

What side effects are possible with Acrocal D?

The officially documented safety profile for Acrocal D (Calcium Carbonate and Dihydrotachysterol) is dominated by the risk of hypercalcemia (excessive calcium in the blood), which is the primary adverse effect noted in regulatory documents for this class of calcitrophic agents. The spectrum of documented adverse reactions is a direct result of this mineral imbalance.

Adverse Reaction Classifications

Adverse effects are classified according to the body systems they affect, reflecting the systemic reach of mineral toxicity. Common effects generally involve the Gastrointestinal System, such as constipation, nausea, vomiting, metallic taste, and dry mouth, and early signs of toxicity, including headache, fatigue, and loss of appetite.

Key affected System-Organ Classes (SOC) include:

  • Metabolism and Nutrition Disorders: Hypercalcemia, hyperphosphatemia.
  • Renal and Urinary Disorders: Polyuria, hypercalciuria, and progressive renal impairment.
  • Nervous System Disorders: Confusion, vertigo, and mental status changes.

Serious Adverse Reactions

The most serious adverse reactions described in official labeling are consequences of chronic or acute high calcium levels. These include metastatic calcification, which involves the deposition of calcium in soft tissues, especially in the blood vessels and kidneys, potentially leading to irreversible renal insufficiency. Acute hypercalcemia can also increase the risk of cardiac arrhythmias and seizures.

Population-Specific Safety Notes

Specific safety considerations are noted for certain patient groups. Individuals with impaired renal function are at a higher risk for toxic effects and ectopic calcification. For patients taking cardiac glycosides (like Digitalis), regulatory texts note that hypercalcemia may predispose them to digitalis toxicity, requiring increased monitoring. Furthermore, some official documents note that use during pregnancy should be restricted due to documented risks of fetal abnormalities associated with hypervitaminosis D in animal studies.

Contraindications in regulatory documents include pre-existing hypercalcemia, malabsorption syndrome, or documented Vitamin D toxicity.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Acrocal D is classified as severe and results primarily in hypercalcemia (excessively high blood calcium levels), which may develop slowly or acutely depending on the exposure. Immediate medical attention is required upon suspicion of overdose to prevent potentially life-threatening outcomes.

Documented overdose manifestations often begin with systemic and gastrointestinal signs. These include anorexia, nausea, vomiting, constipation, headache, and profound lethargy or fatigue. Renal disturbances such as increased thirst (polydipsia) and excessive urination (polyuria) are commonly noted in official labeling.

Severe overdose can escalate to complications affecting vital systems. Officially documented life-threatening outcomes include cardiac arrhythmias and progressive renal impairment that may lead to irreversible renal failure. Neurological signs may advance to confusion, psychosis, or coma. Patients with pre-existing renal impairment are listed as having an increased risk of severe and potentially irreversible damage.

Upon confirmed overdose, the regulatory action is the immediate discontinuation of Acrocal D. Management is entirely symptomatic and supportive, as no specific antidote is known. Officially described supportive measures include vigorous intravenous hydration, specific diet restriction, and procedures like forced diuresis. Continuous monitoring of serum calcium levels and ECG is required during emergency management.

Therapeutic Uses of Acrocal D

What Acrocal D Treats: Main Uses and Benefits

The primary therapeutic role of Acrocal D (Calcium Carbonate and Dihydrotachysterol) is to provide specialized mineral management to treat conditions caused by an inability to maintain normal calcium levels. The core indication for this category of agent is managing hypocalcemia associated with specific chronic diseases.

This medication is generally used for managing conditions resulting from hypocalcemia, including those tied to hypoparathyroidism or pseudohypoparathyroidism, as well as metabolic bone disorders like osteomalacia and specific forms of renal osteodystrophy. It is applied in clinical settings that involve acute or unstable symptom patterns, specifically helping to address groups of symptoms related to heightened physiological activity, such as involuntary muscle spasms (tetany) and uncomfortable paresthesias (tingling and numbness).

“This supportive therapeutic benefit helps maintain a sense of stability when symptoms are more noticeable.”

The combination is relevant for patient groups whose bodies struggle with standard mineral regulation, such as individuals with chronic renal impairment and those requiring postsurgical mineral support. Used in settings marked by temporary physiological imbalance, this specific combination is relevant when supportive symptom management is appropriate, and helps with managing systemic mineral status.


Symptom Management Focus: Neuromuscular Distress The medication helps address symptoms related to heightened physiological activity, such as painful cramping and tingling, which are symptoms that create noticeable physiological strain.

Eligibility and Restrictions for Use

The eligibility for Acrocal D, a typical Calcium and Vitamin D combination product, is defined by strict regulatory contraindications related to conditions that increase calcium or Vitamin D levels in the body.

Populations For Whom Use is Contraindicated

The medicine must not be used by individuals with the following official exclusions:

  • Hypercalcaemia (high calcium levels in the blood) or any condition that leads to it (e.g., myeloma, bone metastases).
  • Hypercalciuria (high calcium levels in the urine) or a history of nephrolithiasis (kidney stones).
  • Hypervitaminosis D (Vitamin D toxicity).
  • Severe renal insufficiency or severe renal impairment (typically defined as a creatinine clearance below 30 , mL/ min).
  • Known hypersensitivity or allergy to the active substances or any excipient in the formulation, including specified allergies to peanut or soya.

Conditional or Restricted Use

Use is not recommended or requires special medical supervision for certain groups, including children and adolescents (typically under 12 years of age, as safety and efficacy may not be established). Caution is also mandated for patients with sarcoidosis or those on prolonged immobilisation due to the increased risk of hypercalcaemia, necessitating regular monitoring of calcium levels.

What should I know about interactions with other medicines?

Acrocal D Interactions with Other Medicines and Products

This section outlines the documented interaction patterns for Acrocal D (Calcium Carbonate and Dihydrotachysterol) as published in government regulatory prescribing information.

Documented Pharmacodynamic Interactions

Interaction Type Interacting Agent(s) Official Constraint/Description
Contraindicated Other Vitamin D Analogues or Pharmacologic Doses of Vitamin D Strictly prohibited due to high risk of severe hypercalcemia (abnormally high calcium levels).
Potentiation Risk Cardiac Glycosides (e.g., Digoxin) May potentiate toxic effects, increasing the risk of severe cardiac arrhythmia.
Additive Effect Thiazide Diuretics Increases the risk or severity of hypercalcemia, particularly in hypoparathyroid patients.

Exposure and Absorption Interactions

Interactions that alter the systemic exposure or absorption of Acrocal D components or co-administered drugs are officially noted:

  • Reduced Efficacy of Dihydrotachysterol: Certain anticonvulsants (e.g., Phenytoin, Phenobarbital) and Rifampicin may reduce the effectiveness of Dihydrotachysterol by accelerating its breakdown.
  • Impaired Absorption of Dihydrotachysterol: Bile Acid Sequestrants (e.g., Cholestyramine) may impair the intestinal absorption of this fat-soluble component.
  • Reduced Absorption of Co-administered Drugs: The Calcium Carbonate component can decrease the absorption of Tetracycline and Fluoroquinolone Antibiotics, as well as Oral Iron Preparations.

Other Official Interaction Notes

  • Dietary Factors: Co-administration with a diet high in oxalic acid (e.g., spinach) or phytic acid (e.g., whole grains) can reduce calcium absorption. Administration should consider a timing separation.
  • Population Note: Patients with hepatic or biliary dysfunction may have altered absorption and metabolic activity of Dihydrotachysterol; renal impairment may increase susceptibility to toxic side effects.

Mechanism of Action

️ VDR Activation and Gene Expression

The regulatory action begins with Dihydrotachysterol (DHT), which undergoes a single hepatic hydroxylation step, allowing its active metabolite to function as an agonist of the nuclear Vitamin D Receptor (VDR). This VDR is primarily located in cells of the small intestine, bone, and kidney. This interaction triggers gene expression, increasing the synthesis of proteins necessary for calcium transport, such as calcium-binding proteins. This mechanism drives the cellular processes required to utilize the mineral substrate.


️ Mineral Provision and Pathway Modulation

The mechanism is completed by the Calcium Carbonate component, which provides a direct, bulk source of elemental calcium ( Ca^2+) in the gastrointestinal tract. The combined action of providing the substrate and activating the absorption machinery (VDR agonism) leads to an elevation of systemic calcium levels. This elevation then serves as a negative feedback signal to the Parathyroid Hormone (PTH) axis, modulating PTH secretion, which influences calcium mobilization from bone and renal excretion. This combined action regulates the systemic mineral environment.

Dosage and Administration Information

How to Use Acrocal D

Acrocal D is an oral combination product containing Calcium Carbonate and Dihydrotachysterol. Its use is guided by a formal two-phase regimen dictated by the Dihydrotachysterol component.

Official Administration and Dosage

Feature Official Labeled Instruction
Route of Administration The product is designed exclusively for oral administration (by mouth) and is available as a tablet, capsule, or solution.
Dosing Schedule Initial Stabilization: Typically 0.8 mg to 2.4 mg of Dihydrotachysterol daily for several days. Maintenance: 0.2 mg to 1.0 mg daily is the typical range, with the average maintenance dose being 0.6 mg daily.
Frequency The prescribed dose is administered once daily (QD) for both initial and long-term maintenance phases.
Administration Time Acrocal D may be taken with or without food.

Procedural Structure and Constraints

The usage protocol begins with a short course of the initial high daily dose to quickly achieve mineral stabilization. This is immediately followed by a transition to the consistent, long-term maintenance dose.

Dose Adjustment: The official protocol requires that all dose changes must be highly individualized and based on periodic laboratory assessments. Adjustments must be performed gradually and at infrequent intervals, often every four to eight weeks, to ensure stable mineral status and prevent overcorrection. The combination inherently provides the concurrent oral calcium required when using Dihydrotachysterol as a calcitrophic agent.

This structured, daily protocol defines the controlled approach to using the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Acrocal D

This section summarizes the structured clinical research for Acrocal D (Calcium Carbonate and Dihydrotachysterol) from regulatory and peer-reviewed scientific sources. The text is a strictly descriptive summary of what has been studied and remains uncertain, and it does not offer advice, dosing instructions, or clinical recommendations.


Evidence for Use in Hypocalcemia Associated with Hypoparathyroidism

Research exploring Dihydrotachysterol was studied for its effects on mineral balance in patients with hypocalcemia (low calcium levels) linked to impaired parathyroid function. This condition is characterized by fluctuating or episodic manifestations, and studies used research contexts involving outcomes related to physical discomfort, such as involuntary muscle spasms and tingling. The evidence base includes randomized controlled trials (RCTs) and long-term observational studies that monitored patients. Research examined the stabilization of serum calcium levels, monitored Parathyroid Hormone (PTH) levels, and reported how symptoms evolved in the observed populations. This evidence contributes to understanding symptom patterns observed in research settings. Long-term outcomes are not fully established when comparing Dihydrotachysterol directly to the most contemporary active agents.

Evidence for Use in Metabolic Bone Disorders

Research has also explored whether Acrocal D was associated with changes in certain metabolic bone disorders, such as osteomalacia and specific forms of renal osteodystrophy. Studies used specialized clinical trials and bone histology studies to examine bone formation rates and mineral content in specific patient groups. The available data show patterns related to mineralization processes, but the evidence quality varies across studies due to research being older, limited by small patient numbers, and comparative evidence is lacking against contemporary treatments.

Research Gaps and Areas of Uncertainty

The available evidence quality varied across studies, with many foundational reports being older or limited by modest sample sizes. Long-term effects are not fully established regarding potential chronic outcomes. Data for certain groups, such as broad populations not affected by severe mineral disorder, remain insufficient. Evidence highlights what is known and what is still uncertain; it describes group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in the studies.

Frequently Asked Questions (FAQ)

Common questions about Acrocal D (FAQ)


Q: What specific conditions is Acrocal D typically prescribed to treat?

According to official product information, this combination medicine is primarily used to manage hypocalcemia (low calcium levels) associated with hypoparathyroidism (impaired parathyroid function) or pseudohypoparathyroidism, as well as specific metabolic bone disorders.


Q: How does the combination of ingredients in Acrocal D benefit bone health?

Acrocal D provides Calcium Carbonate as the necessary building block for bones. The other component, Dihydrotachysterol, activates the Vitamin D Receptor, which in turn increases the synthesis of proteins required to absorb and utilize that calcium for proper bone mineralization.


Q: How long does it usually take to notice the benefits of Acrocal D?

The active ingredient, Dihydrotachysterol, has an intermediate onset of action, with its active metabolite reaching peak levels in the blood within approximately 11 to 12 hours after repeated doses. Achieving full mineral stabilization is a gradual process monitored through periodic laboratory blood tests and dose adjustments.


Q: Can Acrocal D be taken for general health and wellness, not just for a diagnosed deficiency?

Official information indicates that Acrocal D is specifically prescribed for managing certain medical conditions like hypocalcemia. Regulatory labels warn that overdosage of any form of Vitamin D is dangerous and can lead to severe hypercalcemia (abnormally high calcium levels). Use of the medicine is reserved for a diagnosed medical need, and it is not generally indicated for routine supplementation.


Q: Is Acrocal D effective for people with mild bone density loss?

The official labeling for this specific combination focuses on more severe mineral disorders such as hypocalcemia and hypoparathyroidism. While Vitamin D analogs are generally used in the management of bone conditions like osteoporosis, final determination of suitability for conditions like mild bone density loss is made by a healthcare provider, as the drug's primary indications are for more severe mineral disorders.


Q: What is the difference between Acrocal D and other plain calcium supplements?

Acrocal D contains Dihydrotachysterol (DHT), which is a synthetic, potent Vitamin D analog. Plain calcium supplements typically contain only calcium or standard Vitamin D2/D3, which require different activation processes in the body than DHT.


Q: What is the difference between Acrocal D and other plain Vitamin D supplements?

Acrocal D contains Dihydrotachysterol (DHT), a synthetic analog structurally different from standard Vitamin D2 or D3. DHT requires only a single metabolic step for activation, allowing it to more readily regulate mineral metabolism than standard Vitamin D forms.


Q: What should I do if I experience mild stomach upset from Acrocal D?

Mild side effects like dry mouth or changes in bowel habits (such as constipation) are commonly reported. These or other gastrointestinal changes are often managed by the supervising healthcare provider. The occurrence of severe symptoms, such as extreme vomiting or stomach pain, may be signs of serious mineral imbalance and warrants immediate communication with a healthcare professional.


Q: How likely is it to have an allergic reaction to Acrocal D?

While all medicines carry a risk of allergic reaction, the primary serious safety concern for this combination is the risk of severe hypercalcemia. Official contraindications for the medication include known allergy or hypersensitivity to the active ingredients or excipients, such as peanut or soya.


Q: Can I take Acrocal D with my multivitamins?

Regulatory documents state that Acrocal D is strictly prohibited with Other Vitamin D Analogues or Pharmacologic Doses of Vitamin D. Since many multivitamins contain Vitamin D, co-administration with any product containing Vitamin D warrants careful review by a healthcare provider due to the potential for severe hypercalcemia (excessive blood calcium).


Q: Are there any known interactions between Acrocal D and herbal supplements?

Official guidance advises patients to inform their doctor about all other medicines they are taking, including those without a prescription, as well as herbal and complementary medicines. Checking for possible interactions, including those that affect absorption or potency, is standard procedure when prescribing this medication.


Q: Is Acrocal D safe for use during pregnancy or while breastfeeding?

Dihydrotachysterol is classified as a Pregnancy Category C drug. Use during pregnancy is generally restricted due to documented risks of fetal abnormalities associated with hypervitaminosis D in animal studies. Decisions regarding use during pregnancy or breastfeeding are made by the prescribing healthcare provider based on the known risks.


Q: Is it normal to have a metallic taste in my mouth after starting Acrocal D?

Yes, a metallic taste in the mouth is listed among the common adverse effects documented in the official labeling. This symptom is a documented adverse effect and is usually noted during monitoring appointments.


Q: Why is Vitamin D important for calcium absorption?

Active Vitamin D metabolites (like that produced by DHT) play a critical role in mineral balance. They control the intestinal absorption of dietary calcium and promote the synthesis of proteins necessary for calcium transport in the body.


Q: Are there different forms or strengths of Acrocal D available?

Acrocal D is officially available for oral administration as a tablet, capsule, or solution. Dosage strengths of Dihydrotachysterol are available in various forms, and the specific strength used is highly individualized and determined by laboratory assessments.


Q: Do I need regular blood tests while taking Acrocal D?

Yes, official guidance confirms that all dose changes must be highly individualized and based on periodic laboratory assessments. The data from these tests helps the healthcare provider manage the long-term mineral balance.


Q: How does Acrocal D affect parathyroid hormone (PTH) levels?

The active component of Acrocal D works directly on the parathyroid glands to suppress PTH synthesis and secretion. The medicine is used to help regulate the calcium imbalance by contributing to the reduction of elevated PTH levels.


Q: How long can a person safely stay on Acrocal D treatment?

Treatment with Dihydrotachysterol is often intended to be long-term for chronic mineral disorders. However, official warnings note that chronic hypercalcemia can lead to serious consequences, including irreversible kidney damage. Due to this risk, consistent, careful medical monitoring over the course of treatment is required.


Q: Is the calcium in Acrocal D derived from a particular source, like coral or carbonate?

The calcium component in the product is Calcium Carbonate. Regulatory documents specify it is an inorganic salt serving as the principal source of calcium in the fixed-dose combination.


Q: What are the long-term effects of taking Acrocal D continuously?

The most serious long-term risk noted in official warnings is the consequence of chronic high calcium levels, including metastatic calcification. This involves the deposition of calcium in soft tissues, which can potentially lead to irreversible renal damage. Research states that long-term outcomes are not fully established when comparing directly to newer agents.


Q: Can Acrocal D help with muscle weakness or cramps?

Acrocal D is used to correct hypocalcemia, the symptoms of which include muscle cramps, pain, and twitching. Therefore, correcting this mineral imbalance can help alleviate these symptoms. Official documents also list muscle pain as one of the possible, less serious side effects of the drug itself.


Q: Does Acrocal D contain any sugars, artificial sweeteners, or common allergens like soy?

Official safety documents list specific allergies to excipients, noting that individuals with an allergy to peanut or soya are contra-indicated for use. The full and precise list of all ingredients and excipients is available in the manufacturer’s printed patient information leaflet.


Q: Is Acrocal D manufactured with any animal products, making it unsuitable for vegetarians or vegans?

The final dosage form, particularly if it is a soft gelatin capsule, may contain gelatin which is typically animal-derived. For strict dietary needs, the manufacturer’s full ingredient list or excipient section provides specific information regarding the sourcing of components like gelatin.


Q: What signs might indicate that I'm getting too much Vitamin D while on Acrocal D?

Symptoms of too much Vitamin D (Hypervitaminosis D) are often the same as symptoms of high calcium (Hypercalcemia). These can include loss of appetite, dry mouth, metallic taste, nausea, vomiting, increased thirst and urination, and unusual weakness. The occurrence of these signs is noted in regulatory warnings and warrants attention from a healthcare professional.


Q: Can Acrocal D be crushed or chewed, or must it be swallowed whole?

The medicine is generally supplied as an oral tablet or capsule meant to be taken whole. While a liquid form of Dihydrotachysterol does exist, altering the tablet or capsule is considered an unlicensed use. Any alteration to the dosage form is considered an unlicensed use and requires specific authorization from a healthcare provider or pharmacist.


Q: What happens if I occasionally forget to take a dose of Acrocal D?

If a dose is missed, regulatory documents generally advise taking it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. It is important not to take a double dose to make up for a missed one.


Q: Is Acrocal D a prescription-only medicine, or can it be bought over the counter?

The active component, Dihydrotachysterol, is a potent synthetic analog used to manage serious conditions like hypoparathyroidism. The product is not generally available as an over-the-counter medication and is typically a prescription-only (Rx) medicine.

How should Acrocal D be stored and disposed of?

Storage and Environmental Control

Official labeling requires Acrocal D (Calcium Carbonate and Dihydrotachysterol) to be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The product must be strictly protected from direct light, heat, and moisture. It is prohibited to freeze the medication, as this can compromise product integrity.

Packaging and Handling

The medicine must be kept in its original container and the bottle must remain tightly closed when not in use. For safety, Acrocal D must be stored out of the reach and sight of children.

Disposal Instructions

To dispose of expired or unused medication, it is regulatory guidance to not flush it down the toilet or pour it down a drain. If a drug take-back program is unavailable, the recommended procedure is to mix the product with an undesirable substance, seal it in a container, and discard it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acrocal D found in:

A-Z Index: